NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up. “These exciting results were first announced in our press rel ...

Jay Olson from Oppenheimer sets a price target of $30 for Immuneering Corporation (NASDAQ:IMRX), indicating a significant potential upside.Immuneering announces an underwritten public offering of 18.96 million shares, aiming to raise approximately $175 million.The company's stock shows volatility, with a current decrease of 13.33%, amidst its efforts to strengthen its financial position through strategic financial activities.On September 25, 2025, Jay Olson from Oppenheimer set a price target of $30 for Imm ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but those who sign up for the yearly plan will be able to take advantage of a 33.50% dis ...

At 7:35 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading hig ...

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten public offering of 18,959,914 shares of its Class A common stock at an offering price of $9.23 per share, which is equal to the last reported sale price for Immuneering’s Class A common stock on The Nasdaq Global Market on September 24, 2025. In addition, Immuneering has granted the underwriters a 30-d ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a proposed underwritten public offering of shares of its Class A common stock or, in lieu of Class A common stock, pre-funded warrants to purchase Class A common stock (the “Offering”). In addition, Immuneering intends to grant the underwriters a 30-day option to purchase up to a number of additional shares of Class A common stock eq ...

- 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects regulatory feedback on pivotal trial plans in Q4 2025 and, subject to that feedback, expects to initiate pivotal trial by the end of 2025 and begin dosing patients by mid-2026 - NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on k ...

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is a renowned biotech executive and scientist with more than 30 years of leadership in drug discovery and development. He is best known as the founder and longtime CEO and Chairman of ChemoCentryx, where he led the development and eventual F ...

公司数据发布计划 - 计划于2025年9月25日东部时间上午8点举行投资者电话会议 宣布一线胰腺癌患者使用atebimetinib联合mGnP治疗的更新总生存期数据（N=34） 中位随访时间达9个月 [1][6] - 将在2025年PanCAN科学峰会（9月28日）进行数据展示 海报标题为"Atebimetinib + mGnP: Overall Survival and Safety in First Line Pancreatic Cancer Patients" 展示时段为东部时间7:30-8:20和12:20-13:10 [6] - 将于2025年9月17日在第7届RAS靶向药物开发峰会上进行口服报告 主题为"Deep Cyclic Inhibition of MEK: A Transformational Approach to Durable and Safe Combinations in RAS-Mutant Cancers" 报告时间为东部时间16:15 [6] 临床数据表现 - 一线胰腺癌患者使用atebimetinib联合mGnP治疗6个月总生存率达到94% 显著高于标准护理方案GnP的67% [3] - 标准护理方案GnP治疗9个月时总生存率急剧下降至约47% 而atebimetinib组合9个月中位随访数据即将公布 [3] - 药物设计注重持久性和耐受性 旨在帮助患者延长生存期且避免严重副作用 [3] 产品研发进展 - 主要候选产品atebimetinib（IMM-1-104）是口服每日一次的MEK深度循环抑制剂 目前处于治疗晚期实体瘤（包括胰腺癌）的2a期临床试验阶段 [4] - 开发管线包含早期阶段项目 专注于开发全新癌症药物类别——深度循环抑制剂 [4] - 公司专注于MAPK通路驱动肿瘤的治疗 其中胰腺癌为主要适应症方向 [4] 行业会议参与 - 将在两个重要科学会议上进行展示：2025年PanCAN科学峰会和第7届RAS靶向药物开发峰会 [1][6] - 通过行业会议分享临床前数据深度循环抑制剂的研究成果 [5][6] - 与胰腺癌行动网络（PanCAN）合作 向肿瘤学界传递最新治疗进展 [3]

交易概述 - 公司完成私募配售 总前期毛收益约2500万美元 扣除费用前 [1] - 配售对象为顶级机构和合格投资者 [1] 证券发行细节 - 发行6,329,113股未注册A类普通股 每股价格3.95美元 [2] - 部分投资者获得预融资认股权证 每股价格3.949美元 [2] - 附带购买认股权证可认购2,848,096股A类普通股 行权价每股5.50美元 [2] - 认股权证行权期为五年 自相关股票注册登记后起算 [2] - 投资者获得注册权 [2] - 证券未按证券法注册 不得在美转售除非符合豁免或注册要求 [3] 财务顾问 - Leerink Partners担任本次私募配售财务顾问 [4] 公司业务背景 - 公司为临床阶段肿瘤学企业 专注于延长癌症患者生存期 [5] - 开发全新癌症药物类别"深度循环抑制剂" [5] - 主要候选产品atebimetinib（IMM-1-104）为口服每日一次MEK抑制剂 [5] - 当前进行针对晚期实体瘤（含胰腺癌）的2a期试验 [5] - 研发管线包含早期阶段项目 [5]